Navigation Links
Solos Endoscopy, Inc. Develops Specialized Endocoupler for the MammoView(TM)
Date:4/2/2009

BOSTON, April 2 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (OTC Pink Sheets: SNDY) is pleased to announce that the Company has developed a new endocoupler with an eye piece for the MammoView(TM) system. Along with its current endocoupler, it will allow the MammoView scope to be used by a majority of the video systems currently in the market place. Solos has already started to market the new endocoupler to those customers that previously could not utilize the standard endocoupler. The new MammoView Endocoupler will allow healthcare facilities to have more flexibility because it allow them to utilize any video system at their disposal.

"The new MammoView(TM) endocoupler enables us to offer the MammoView system to a wider customer base that was previously excluded because of the incompatibility of the original endocoupler," stated Bob Segersten, President of Solos Endoscopy, Inc.

Solos Endoscopy recently announced that the Company received a purchase order for its MammoView(TM) line of surgical endoscopy instruments from Sharp Healthcare, one of the leading healthcare providers in the San Diego region.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that
'/>"/>

SOURCE Solos Endoscopy, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Solos Endoscopy, Inc. Receives Purchase Order from Leading San Diego Healthcare Provider
2. Solos Endoscopy, Inc. Successfully Completes FDA Inspection
3. Solos Endoscopy, Inc. Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM)
4. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in January Issue of Outpatient Surgery Magazine
5. Solos Endoscopy, Inc.s MammoView(TM) Featured in December Issue of Surgical Products Magazine
6. Solos Endoscopy, Inc. Posts First Nine Months Financials for 2008 on Pinksheets.com
7. Solos Endoscopy, Inc. Receives Purchase Order from Cleveland Clinic
8. Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year
9. Solos Endoscopy, Inc.s Mammo View(TM) System Now Used in Womens Hospital of Baton Rouge, LA
10. Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com
11. Siemens Further Develops its syngo Dynamics Solution
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 1Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 2Beckman Coulter Announces the Creation of Beckman Coulter Genomics 54297 1Beckman Coulter Announces the Creation of Beckman Coulter Genomics 54297 2Beckman Coulter Announces the Creation of Beckman Coulter Genomics 54297 3Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 1Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 2Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 3